Head and neck cancer: From anatomy to biology

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2013-2023

  Bose, Pinaki ^a   Brockton, Nigel T ^b   Dort, Joseph C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

EGFR; head and neck squamous cell carcinoma; HPV; JAK STAT; PI3K

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; EPIDERMAL GROWTH FACTOR; GUANOSINE TRIPHOSPHATASE; MEMBRANE RECEPTOR; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PROTEIN TYROSINE KINASE; STAT PROTEIN;

AUTOPHOSPHORYLATION; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CELL CYCLE PROGRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXIA; MUTAGENESIS; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT RESPONSE;

EGFR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HPV; JAK-STAT; PI3K;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 84882571069     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28112     Document Type: Review

References (159)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Warnakulasuriya S,. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-16.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Crile G, III,. On the technique of operations upon the head and neck. Ann Surg 1906; 44: 842-50.
5. Nowak F, Soria JC, Calvo F,. Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 2012; 9: 479-86.
6. Sturgis EM, Cinciripini PM,. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110: 1429-35.
7. Schlecht NF, Franco EL, Pintos J, et al. Effect of smoking cessation and tobacco type on the risk of cancers of the upper aero-digestive tract in Brazil. Epidemiology 1999; 10: 412-8.
8. Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007; 99: 777-89.
9. Pelucchi C, Gallus S, Garavello W, et al. Alcohol and tobacco use, and cancer risk for upper aerodigestive tract and liver. Eur J Cancer Prev 2008; 17: 340-4.
10. Marur S, D'Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-9.
11. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-56.
12. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307: 693-703.
13. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377: 932-40.
14. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324: 17-27.
15. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-20.
16. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
17. Whitfield ML, George LK, Grant GD, et al. Common markers of proliferation. Nat Rev Cancer 2006; 6: 99-106.
18. Molinolo AA, Amornphimoltham P, Squarize CH, et al. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009; 45: 324-34.
19. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
20. Dyson N, Howley PM, Munger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
21. Benevolo M, Mottolese M, Marandino F, et al. Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 2006; 19: 384-91.
22. Kuo KT, Hsiao CH, Lin CH, et al. The biomarkers of human papillomavirus infection in tonsillar squamous cell carcinoma-molecular basis and predicting favorable outcome. Mod Pathol 2008; 21: 376-86.
23. Ragin CC, Taioli E, Weissfeld JL, et al. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer 2006; 95: 1432-8.
24. Lewis JS, Jr,., Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010; 34: 1088-96.
25. Harris SL, Thorne LB, Seaman WT, et al. Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck 2011; 33: 1622-7.
26. McLaughlin-Drubin ME, Crum CP, Munger K,. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 2011; 108: 2130-5.
27. Straight SW, Hinkle PM, Jewers RJ, et al. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993; 67: 4521-32.
28. Ragin CC, Taioli E,. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-20.
29. Leemans CR, Braakhuis BJ, Brakenhoff RH,. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22.
30. Rothenberg SM, Ellisen LW,. The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest 2012; 122: 1951-7.
31. Bolt J, Vo QN, Kim WJ, et al. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol 2005; 41: 1013-20.
32. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-61.
33. Shaw R,. The epigenetics of oral cancer. Int J Oral Maxillofac Surg 2006; 35: 101-8.
34. Ha PK, Califano JA,. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006; 7: 77-82.
35. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154-7.
36. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-60.
37. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3.
38. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, et al. Genetic and molecular alterations associated with oral squamous cell cancer (Review). Oncol Rep 2009; 22: 1277-82.
39. Smeets SJ, Brakenhoff RH, Ylstra B, et al. Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cell Oncol 2009; 31: 291-300.
40. Dominguez G, Silva J, Garcia JM, et al. Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res 2003; 530: 9-17.
41. Ogi K, Toyota M, Ohe-Toyota M, et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 2002; 8: 3164-71.
42. Sailasree R, Abhilash A, Sathyan KM, et al. Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 414-20.
43. Tribius S, Ihloff AS, Rieckmann T, et al. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett 2011; 304: 71-9.
44. Paclitaxel, cisplatin, and cetuximab followed by cetuximab and intensity-modulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery; NCT01084083. Available at: http://www.clinicaltrials.gov/. Accessed on October 19, 2012.
45. Radiation therapy with cisplatin or cetuximab in treating patients with oropharyngeal cancer; NCT01302834. Available at: http://www.clinicaltrials.gov/. Accessed on October 19, 2012.
46. Harris M, Wang XG, Jiang Z, et al. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. Head Neck Oncol 2011; 3: 9.
47. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47.
48. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802-8.
49. Lo HW, Hsu SC, Ali-Seyed M, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7: 575-89.
50. Wheeler S, Siwak DR, Chai R, et al. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 2012; 18: 2278-89.
51. Hama T, Yuza Y, Saito Y, et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009; 14: 900-8.
52. Ozanne B, Richards CS, Hendler F, et al. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 1986; 149: 9-14.
53. Grandis JR, Tweardy DJ,. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-84.
54. Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2011; 22: 1078-87.
55. Quon H, Liu FF, Cummings BJ,. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23: 147-59.
56. Choong NW, Cohen EE,. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol 2006; 57: 25-43.
57. Vivanco I, Sawyers CL,. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
58. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
59. Bernier J, Bentzen SM, Vermorken JB,. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 2009; 6: 266-77.
60. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
61. Takes RP, Baatenburg de Jong RJ, Schuuring E, et al. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res 1998; 18: 4793-800.
62. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
63. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27.
64. Wheeler DL, Dunn EF, Harari PM,. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493-507.
65. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-73.
66. Sharafinski ME, Ferris RL, Ferrone S, et al. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010; 32: 1412-21.
67. Tinhofer I, Klinghammer K, Weichert W, et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2011; 17: 5197-204.
68. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007; 104: 4071-6.
69. Yang L, Jiang H, Shi B, et al. Identification and characterization of Ch806 mimotopes. Cancer Immunol Immunother 2010; 59: 1481-7.
70. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 4722-9.
71. McIntyre JB, Bose P, Klimowicz AC, et al. Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma. PLoS One 2012; 7: e31723.
72. Mandal M, Myers JN, Lippman SM, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008; 112: 2088-100.
73. Basu D, Nguyen TT, Montone KT, et al. Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene 2010; 29: 4170-82.
74. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27: 3944-56.
75. Engelman JA, Luo J, Cantley LC,. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-19.
76. Steelman LS, Chappell WH, Abrams SL, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3: 192-222.
77. Murugan AK, Hong NT, Fukui Y, et al. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol 2008; 32: 101-11.
78. Qiu W, Schonleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 1441-6.
79. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10: 558-65.
80. Faber AC, Li D, Song Y, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 2009; 106: 19503-8.
81. Study of PX-866 and Docetaxel in Solid Tumors; NCT01204099. Available at: http://www.clinicaltrials.gov/. Accessed on October 17, 2012.
82. Phase 1 and 2 study of PX-866 and cetuximab; NCT01252628. Available at: http://www.clinicaltrials.gov/. Accessed on October 17, 2012.
83. MK2206 in treating patients with recurrent or metastatic head and neck cancer; NCT01349933. Available at: http://www.clinicaltrials.gov/. Accessed on October 17, 2012.
84. Rapamycin therapy in head and neck squamous cell carcinoma; NCT01195922. Available at: http://www.clinicaltrials.gov/. Accessed on October 17, 2012.
85. Fury MG, Sherman E, Ho A, et al. A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer Chemother Pharmacol 2012; 70: 121-8.
86. Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC); NCT01016769. Available at: http://www.clinicaltrials.gov/. Accessed on January 23, 2013.
87. Khariwala SS, Kjaergaard J, Lorenz R, et al. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 2006; 116: 814-20.
88. Patel V, Marsh CA, Dorsam RT, et al. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 2011; 71: 7103-12.
89. Molinolo AA, Marsh C, El Dinali M, et al. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res 2012; 18: 2558-68.
90. A Study of Carboplatin, Cetuximab and RAD001 in advanced head and neck cancer; NCT01283334. Available at: http://www.clinicaltrials.gov/. Accessed on January 23, 2013.
91. Trial of RAD001 and Erlotinib with recurrent head and neck squamous cell carcinoma; NCT00942734. Available at: http://www.clinicaltrials.gov/. Accessed on January 23, 2013.
92. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-3.
93. LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50.
94. Limnander A, Rothman PB,. Abl oncogene bypasses normal regulation of Jak/STAT activation. Cell Cycle 2004; 3: 1486-8.
95. Henderson YC, Guo XY, Greenberger J, et al. Potential role of bcr-abl in the activation of JAK1 kinase. Clin Cancer Res 1997; 3: 145-9.
96. Sriuranpong V, Park JI, Amornphimoltham P, et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003; 63: 2948-56.
97. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest 1998; 102: 1385-92.
98. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227-32.
99. Nagpal JK, Mishra R, Das BR,. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 2002; 94: 2393-400.
100. Arredondo J, Chernyavsky AI, Jolkovsky DL, et al. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 2006; 20: 2093-101.
101. Koppikar P, Lui VW, Man D, et al. Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res 2008; 14: 7682-90.
102. Xi S, Zhang Q, Gooding WE, et al. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res 2003; 63: 6763-71.
103. Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012; 119: 4614-8.
104. Ruxolitinib phosphate (oral JAK inhibitor INCB18424) in treating patients with relapsed or refractory diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma following donor stem cell transplant; NCT01431209.
105. Tefferi A,. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012; 119: 2721-30.
106. Lai SY, Johnson FM,. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 2010; 13: 67-78.
107. Sen M, Thomas SM, Kim S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2012; 2::694-705.
108. Sen M, Joyce S, Panahandeh M, et al. Targeting Stat3 abrogatesegfr inhibitor resistance in cancer. Clin Cancer Res 2012; 18::4986-96.
109. Dent P, Curiel DT, Fisher PB, et al. Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat 2009; 12: 65-73.
110. Isa AY, Ward TH, West CM, et al. Hypoxia in head and neck cancer. Br J Radiol 2006; 79: 791-8.
111. Rofstad EK, Galappathi K, Mathiesen B, et al. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 2007; 13: 1971-8.
112. Janssen HL, Haustermans KM, Balm AJ, et al. Hypoxia in head and neck cancer: how much, how important? Head Neck 2005; 27: 622-38.
113. Nizet V, Johnson RS,. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009; 9: 609-17.
114. Sullivan R, Graham CH,. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007; 26: 319-31.
115. Semenza GL,. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-14.
116. Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, et al. Hypoxia-inducible factors in OSCC. Cancer Lett 2011; 313: 1-8.
117. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-43.
118. Shi Q, Le X, Wang B, et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 2001; 20: 3751-6.
119. Gatenby RA, Gillies RJ,. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008; 8: 56-61.
120. Svastova E, Zilka N, Zat'ovicova M, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 2003; 290: 332-45.
121. Sorensen BS, Hao J, Overgaard J, et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 2005; 76: 187-93.
122. Robertson N, Potter C, Harris AL,. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004; 64: 6160-5.
123. Raghunand N, Gatenby RA, Gillies RJ,. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 2003; 76 Spec No 1: S11-22.
124. Brockton N, Dort J, Lau H, et al. High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011; 80: 249-57.
125. Brockton NT, Klimowicz AC, Bose P, et al. High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma. Oral Oncol 2012; 48: 615-22.
126. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48.
127. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-9.
128. Overgaard J,. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 2011; 100: 22-32.
129. Kaanders JH, Bussink J, van der Kogel AJ,. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002; 3: 728-37.
130. Toustrup K, Sorensen BS, Lassen P, et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012; 102: 122-9.
131. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010; 94: 30-5.
132. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-8.
133. Hay MP, Hicks KO, Pruijn FB, et al Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. J Med Chem 2007;50: 6392-404.
134. Xia Q, Zhang L, Zhang J, et al. Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives. Eur J Med Chem 2011; 46: 919-26.
135. Jameson MB, Rischin D, Pegram M, et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 2010; 65: 791-801.
136. Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 2011; 99: 424-31.
137. McDonald PC, Winum JY, Supuran CT, et al. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012; 3: 84-97.
138. Garzon R, Marcucci G, Croce CM,. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-89.
139. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
140. Croce CM,. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-14.
141. Chang SS, Jiang WW, Smith I, et al. MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 2008; 123: 2791-7.
142. Ramdas L, Giri U, Ashorn CL, et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 2009; 31: 642-54.
143. Hui AB, Lenarduzzi M, Krushel T, et al. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 2010; 16: 1129-39.
144. Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009; 15: 5473-7.
145. Tran N, McLean T, Zhang X, et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 2007; 358: 12-7.
146. Childs G, Fazzari M, Kung G, et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 2009; 174: 736-45.
147. Henson BJ, Bhattacharjee S, O'Dee DM, et al. Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer 2009; 48: 569-82.
148. Chen Z, Jin Y, Yu D, et al. Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. Oral Oncol 2012; 48: 686-91.
149. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-47.
150. Scott GK, Goga A, Bhaumik D, et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-86.
151. Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-4.
152. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
153. Wong TS, Liu XB, Chung-Wai Ho A, et al. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 2008; 123: 251-7.
154. Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008; 28: 2167-74.
155. Cervigne NK, Reis PP, Machado J, et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet 2009; 18: 4818-29.
156. Tang JT, Wang JL, Du W, et al. MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 2011; 32: 1207-15.
157. Avissar M, Christensen BC, Kelsey KT, et al. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15: 2850-5.
158. Fletcher AM, Heaford AC, Trask DK,. Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific mir-205. Transl Oncol 2008; 1: 202-8.
159. Qu C, Liang Z, Huang J, et al. MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle 2012; 11.